The ANLN Knockout A2780 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population generated from the A2780 human ovarian carcinoma line. This pooled population carries heterogeneous disruptive edits in the ANLN gene, providing a loss-of-function model to study anillin-dependent processes. The polyclonal format avoids single-cell cloning artifacts and is suitable for bulk functional assays where a mixed genetic background is acceptable.
The A2780 cell line, derived from an untreated patient with ovarian endometrioid adenocarcinoma, is a widely used model for investigating cisplatin sensitivity and resistance. Its established utility in ovarian cancer research makes it an ideal host for evaluating the tumorigenic roles of ANLN, including effects on proliferation, apoptosis, and chemotherapeutic response.
ANLN encodes anillin, an actin-binding scaffold critical for cytokinesis. It crosslinks actin filaments and recruits myosin II and septins (SEPT2, SEPT6, SEPT7) to the cleavage furrow, ensuring proper furrow positioning and ingression. ANLN activity is controlled by CDK1 phosphorylation at mitotic entry and RhoA GTPase signaling through effectors like ROCK and mDia2. Transcriptional regulation involves E2F factors and MYC, with additional input from PI3K/AKT signaling. Disruption of ANLN causes cytokinesis failure, leading to binucleation and polyploidy, while overexpression in cancer drives proliferation and genomic instability.
In ovarian carcinoma, ANLN overexpression correlates with poor prognosis, making knockout in A2780 cells a valuable model to dissect its mitotic functions and contribution to genomic instability. Researchers can examine cytokinesis defects, polyploidy induction, and altered sensitivity to cisplatin or paclitaxel. The model also enables studies on ANLN-dependent cytoskeletal dynamics affecting migration and invasion, key processes in metastasis.
Researchers may perform western blotting and RT-qPCR for knockout validation, cell proliferation (MTT/BrdU) assays, flow cytometry for cell cycle and ploidy, immunofluorescence of actin and anillin, and migration/invasion tests via Boyden chambers. Drug sensitivity studies, such as cisplatin IC50 determination, are also applicable. For additional information, please contact Ascent Research.
